High levels of circulating endothelial microparticles in patients with acute coronary syndromes

American Heart Journal

Volumn 145, Issue 6, 2003, Pages 962-970

  Bernal Mizrachi, Leon ^a   Jy, Wenche ^a   Jimenez, Joaquin J ^a   Pastor, Juan ^a   Mauro, Lucia M ^a   Horstman, Lawrence L ^a   De Marchena, Eduardo ^a   Ahn, Yeon S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CD31 ANTIGEN; CD42 ANTIGEN; CD51 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; MEMBRANE ANTIGEN; NANOPARTICLE; NITRATE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; THROMBIN RECEPTOR;

ADULT; AGED; ARTICLE; ASSAY; BLOOD VESSEL INJURY; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFECT; ENDOTHELIAL MICROPARTICLE; ENDOTHELIAL MICROPARTICLE ASSAY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STABLE ANGINA PECTORIS; THROMBOCYTE; THROMBOCYTE MICROPARTICLE; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; ANGINA PECTORIS; BLOOD; METABOLISM; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; SYNDROME;

ADULT; AGED; ANGINA PECTORIS; ANGINA, UNSTABLE; ANTIGENS, CD31; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHAV; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROSPECTIVE STUDIES; SYNDROME;

EID: 0038620493     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00103-0     Document Type: Article

References (47)

1. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
2. Libby P. Current concepts in the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
3. Libby P, Ridkin PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
4. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999;104:93-102.
5. Jimenez J, Jy W, Mauro L, et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura (TTP): findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001;112:81-90.
6. Mallat Z, Hugel B, Ohan J, et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999;99:348-53.
7. Bernal-Mizrachi L, Jy W, Horstman LL, et al. Disturbance of endothelium in acute coronary syndromes monitored with flowcytometric assay of endothelial microparticles (EMP). Blood 2000;96:270a.
8. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary symptoms. Circulation 2000;101:841-3.
9. Minagar A, Jy W, Jimenez J, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neuralogy 2001;56:1319-24.
10. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999;30:111-42.
11. Jy W, Horstman LL, Arce M, et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992;119:334-45.
12. Gibbons R, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. Circulation 1999;99:2829-48.
13. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. New Engl J Med 2000;343:1139-47.
14. Venge P, Lagerqvist B, Diderholm E, et al. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol 2002;89:1035-41.
15. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001;286:2405-12.
16. Katopodis JN, Kolodny L, Jy W, et al. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol 1997;54:95-101.
17. Ware JA, Heistad DD. Platelet-endothelium interactions. New Engl J Med 1993;328:628-35.
18. Casciola-Rosen L, Rosen A, Petri M, et al. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996;93:1624-9.
19. Mallat Z, Ohan J, Leseche G, et al. Colocalization of CPP-32 with apoptotic cells in human atherosclerotic plaques. Circulation 1997;96:424-8.
20. Sabatier F, Roux V, Anfosso F, et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Hemost Thromb Vasc Biol 2002;99:3962-70.
21. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003 (in press).
22. Aupeix K, Hugel B, Martin T, et al. The significance of shed membrane microparticles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997;99:1546-54.
23. Arnout J. The pathogensis of the anti-phospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996;75:536-41.
24. Karimova A, Pinsky DJ. The endothelial response to oxygen deprivation: biology and clinical implications. Intensive Care Med 2001;27:19-31.
25. Zund G, Nelson DP, Neufeld EJ, et al. Hypoxia enhances stimulus-dependent inducation of E-selectin on aortic endothelial cells. Proc Natl Acad Sci USA 1996;93:7075-80.
26. Franogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
27. Combes V, Simon A, Grau G, et al. In vitro DUPE use 551. J Clin Invest 1999;104:93-102.
28. Shaw SK, Perkins BN, Lim YC, et al. Reduced expression of junctional adhesion molecules and platelet/endothelial cell adhesion molecule-1 (CD31) at human vascular endothelial junctions by cytokines tumor necros factor-alpha plus interferon-gamma does not reduce leukocyte transmigration under flow. Am J Pathol 2001;159:2281-91.
29. Taubes G. News focus: does inflammation cut to the heart of the matter? Science 2002;296:242-5.
30. Entman ML, Michael L, Rossen RD, et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991;5:2529-qd;j37.
31. Hamilton KK, Hattori R, Esmon CT, et al. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990;265:3809-14.
32. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-6.
33. Mirow N, Brinkmann T, Minami K, et al. Low dose systemic heparinization combined with heparin-coated extraqcorporeal circulation: effects related to platelets. J Cardiovasc Surg (Torino) 2001;42:579-85.
34. Kruse-Elliott KT, Chaban K, Grossman JE, et al. Low molecular weight heparin alters porcine neutrophil responses to platelet activating factor. Shock 1998;10:98-202.
35. Weiler JM, Edens RE, Linhardt RJ, et al. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992;148:3210-5.
36. Ferer-Lopez P, Renesto P, Prevost MC, et al. Heparin inhibits neutrophil-induced platelet activation via cathepsin G. J Lab Clin Med 1992;119:231-9.
37. Sandset PM, Abildgaard U, Larsen ML. Heparin induced release of intrinsice coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-13.
38. Cadroy Y, Gaspin D, Dupouy D, et al. Heparin reverses the procoagulant properties of stimulated endothelial cells. Thromb Haemost 1996;75:190-5.
39. Sogo N, Magid KS, Shaw CA, et al. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun 2000;279:412-9.
40. Lam JY, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. Circulation 1988;78:712-6.
41. Martorana PA, Goebel B, Ruetten H, et al. Coronary endothelial dysfunction after ischemia and reperfusion in the dog: a functional and morphological investigation. Basic Res Cardiol 1998;93:257-63.
42. Abrams J. Beneficial actions of nitrates in cardiovascular diseases. Am J Cardiol 1996;77:31-7C.
43. Jy W, Mao WW, Horstman LL, et al. A flow cytometric assay of platelet activation marker P-selectin (CD62p) distinguishes heparin-induced thrombocytopenia (HIT) from HIT-with-thrombosis (HITT). Thromb Haemost 1999;82:1255-9.
44. Lee DH, Warkentin TE, Denomme GA, et al. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haemotol 1996;95:724-31
45. Warkentin TE. Heparin-induced thrombocytopenia and its treatment. J Thromb Thrombol 2000;9(1 Suppl):S29-35.
46. Lazar HL, Bao Y, Rivers S, et al. High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size. Ann Thorac Surg 2001;72:548-54.
47. Wang SJ, Ballantyne CM, Sharrett R, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 1997; 96:4219-25.